临床肺科杂志
臨床肺科雜誌
림상폐과잡지
Journal of Clinical Pulmonary Medicine
2015年
12期
2243-2245
,共3页
小儿肺炎%腹泻%双歧杆菌三联活菌胶囊
小兒肺炎%腹瀉%雙歧桿菌三聯活菌膠囊
소인폐염%복사%쌍기간균삼련활균효낭
children with pneumonia%diarrhea%bifid triple viable capsule
目的：观察双歧杆菌三联活菌胶囊防治小儿肺炎继发腹泻的疗效及安全性。方法选取我院治疗的240例小儿肺炎患儿作为研究对象,并随机分观察组和对照组,每组各120例患儿。对照组患儿采用常规治疗,观察组患儿在对照组的基础上加用双歧杆菌三联活菌胶囊进行治疗。观察比较两组患儿肺炎继发腹泻发生、腹泻治疗和药物不良反应情况以评价双歧杆菌三联活菌胶囊的治疗效果。结果观察组108例患儿完成研究,对照组111例患儿完成研究；观察组患儿肺炎继发腹泻发生率为21．30%,明显低于对照组的43．24%,其差异有统计学意义(χ2=12．034,P<0．001)；观察组患儿腹泻严重程度明显轻于对照组,其差异有统计学意义(Z=-3．055,P<0．01)；观察组患儿腹泻平均痊愈时间为(6．23±3．83) d,明显短于对照组的9．96±4．79d,其差异有统计学意义(t=-3．210,P<0．01)；观察组与对照组患儿均未观察到明显药物不良反应。结论双歧三联活菌胶囊可以显著降低患儿肺炎继发腹泻的发生率,减轻患儿腹泻的严重程度,缩短患儿腹泻治疗时间,同时无明显药物不良反应,是一种安全可靠的治疗方法,值得在临床推广应用。
目的：觀察雙歧桿菌三聯活菌膠囊防治小兒肺炎繼髮腹瀉的療效及安全性。方法選取我院治療的240例小兒肺炎患兒作為研究對象,併隨機分觀察組和對照組,每組各120例患兒。對照組患兒採用常規治療,觀察組患兒在對照組的基礎上加用雙歧桿菌三聯活菌膠囊進行治療。觀察比較兩組患兒肺炎繼髮腹瀉髮生、腹瀉治療和藥物不良反應情況以評價雙歧桿菌三聯活菌膠囊的治療效果。結果觀察組108例患兒完成研究,對照組111例患兒完成研究；觀察組患兒肺炎繼髮腹瀉髮生率為21．30%,明顯低于對照組的43．24%,其差異有統計學意義(χ2=12．034,P<0．001)；觀察組患兒腹瀉嚴重程度明顯輕于對照組,其差異有統計學意義(Z=-3．055,P<0．01)；觀察組患兒腹瀉平均痊愈時間為(6．23±3．83) d,明顯短于對照組的9．96±4．79d,其差異有統計學意義(t=-3．210,P<0．01)；觀察組與對照組患兒均未觀察到明顯藥物不良反應。結論雙歧三聯活菌膠囊可以顯著降低患兒肺炎繼髮腹瀉的髮生率,減輕患兒腹瀉的嚴重程度,縮短患兒腹瀉治療時間,同時無明顯藥物不良反應,是一種安全可靠的治療方法,值得在臨床推廣應用。
목적：관찰쌍기간균삼련활균효낭방치소인폐염계발복사적료효급안전성。방법선취아원치료적240례소인폐염환인작위연구대상,병수궤분관찰조화대조조,매조각120례환인。대조조환인채용상규치료,관찰조환인재대조조적기출상가용쌍기간균삼련활균효낭진행치료。관찰비교량조환인폐염계발복사발생、복사치료화약물불량반응정황이평개쌍기간균삼련활균효낭적치료효과。결과관찰조108례환인완성연구,대조조111례환인완성연구；관찰조환인폐염계발복사발생솔위21．30%,명현저우대조조적43．24%,기차이유통계학의의(χ2=12．034,P<0．001)；관찰조환인복사엄중정도명현경우대조조,기차이유통계학의의(Z=-3．055,P<0．01)；관찰조환인복사평균전유시간위(6．23±3．83) d,명현단우대조조적9．96±4．79d,기차이유통계학의의(t=-3．210,P<0．01)；관찰조여대조조환인균미관찰도명현약물불량반응。결론쌍기삼련활균효낭가이현저강저환인폐염계발복사적발생솔,감경환인복사적엄중정도,축단환인복사치료시간,동시무명현약물불량반응,시일충안전가고적치료방법,치득재림상추엄응용。
Objective To observe the clinical efficiency of bifid triple viable capsules in preventing and treating diarrhea children with pneumonia. Methods 240 children with pneumonia were selected and randomly di-vided into the experimental group and the control group. Children in the control group received routine treatment, while the experimental group received bifid triple viable capsules and routine therapy. The incidence, severity and duration of treatment of diarrhea and adverse reaction were analyzed. Results There were 108 children in the experi-mental group and 111 children in the control group completed with this trial. The incidence of diarrhea in the experi-mental group was 21. 30%, which was significantly lower than in the control group (43. 42%) (χ2 =12. 034, P<0. 001). The severity of children with diarrhea in the experimental group were significantly lower than that in the con-trol group (Z= -3. 055, P<0. 01). The cure time in the experimental group was (6. 23 ± 3. 83) d, which were significantly shorter than that in the control group (9. 96 ± 4. 79d) (t= -3. 210, P<0. 01). No drug adverse reac-tion was observed in both groups. Conclusion Bifid triple viable capsules can reduce the incidence, the severity and cure time of diarrhea, which is worthy of widely clinical practice.
